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INTRODUCTION
The telomere, located at the end of the eukaryotic chromo-
some, is a specialized structure that consists of six TTAGGG
bases in a repetitive pattern (1). Its role is to protect the chro-
mosomes from DNA degradation, end-to-end fusions, rear-
rangement, and loss (2). For every cell division, 50-200 nu-
cleotides are decreased during the aging of normal cells. As
the telomere becomes shorter, it finally reaches a stage when
apoptotic cell death is inevitable. This shortening process of
the telomere may control the proliferative capacity of normal
cells, and may be associated with aging process (3-6).
Telomerase is a type of ribonucleoprotein which adds hex-
americ repeats of 5′ -TTAGGG-3′ to the end of telomeres to
preserve the length of the chromosome. It does not express
on normal somatic cells, but is instead expressed on immor-
talized cells, such as tumor cells (7, 8). Telomerase activity
can be an index of malignant potential or malignancy itself
in brain tumors. The presence of telomerase in a certain tumor
results in a worse prognosis than a tumor without telomerase.
A tumor with less or no telomerase activity has been found
to have a better prognosis (9-11). On the other hand, cells
that are telomerase positive have stronger survival and higher
resistance against apoptosis (5). The fact that these cells are
more susceptible to death when the action of telomerase is
blocked proves that telomerase has a definite role in cell death
and prognosis.
In order to investigate whether the expression of telomerase
can be used as a prognostic factor, we studied the relationship
between telomerase activity and survival in 62 patients with
brain tumors.
MATERIALS AND METHODS
Patients and pathological diagnosis
Between March 1998 and December 1999, 93 consecutive
patients with brain tumors were treated with surgical resec-
tion. A total of 62 of the cases with brain tumors had avail-
able surgical specimens. All tumor tissue was obtained at
the time of surgery, frozen as rapidly as possible, and stored
at -80℃until subjected to assay. 
The pathological types of brain tumors were classified
according to World Health Organization (WHO) classifica-
tion (13). They consisted of 16 astrocytic tumors, including
6 astrocytomas, 4 anaplastic astrocytomas, and 6 glioblas-
tomas, 16 meningiomas, 12 pituitary adenomas, 9 metastatic
brain tumors, 6 acoustic neurinomas, 2 pineoblastomas, and
a hemangioblastoma. We also categorized the patients patho-
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Prognostic Implication of Telomerase Activity in Patients with Brain
Tumors
Telomerase adds telomeric repeats to the ends of telomeres to compensate for their
progressive loss. A favorable prognosis is associated with low or no telomerase in
some tumors. The authors investigated whether telomerase activity is associated
with survival of patients with brain tumors. Sixty-two consecutive patients with brain
tumors underwent surgery, and their surgical specimens were investigated. The
patients were pathologically categorized as group I (aggressive group) and group
II (non-aggressive group). Telomerase activity was examined by the telomeric repeat
amplification protocol (TRAP) assay. The median time was calculated in associa-
tion with overall survival and progression-free survival in each group. The significant
difference was noted in telomerase activity between high-grade gliomas and low-
grade gliomas (p=0.022). Telomerase activity was significantly associated with the
median overall survival and progression-free survival in all tumors of the aggressive
group. On the other hand, the median overall survival in the non-aggressive group
was not dependent on telomerase activity, while the median progression-free sur-
vival was. Our data suggests that telomerase is an important prognostic indicator
of survival in patients with brain tumors. 
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logically as aggressive group (group I) and non-aggressive
group (group II). In the aggressive group, astrocytic tumors,
pineoblastoma, and metastatic tumors were included. The
remaining tumors, including pituitary adenoma, meningioma,
acoustic neurinoma, and hemangioblatoma, were categorized
as the non-aggressive group. Gliomas were also classified into
high-grade gliomas, including anaplastic astrocytoma and
glioblastoma, and low-grade glioma including astrocytoma.
After surgery, clinical follow-up data were obtained from
patients. Follow-up imaging studies were requested at 1, 3,
6, and 12 months for the first year and at 6-month intervals
thereafter. The follow-up period was censored on December
2003. Survival time was measured as the time from the date
of the initial surgery to the date of death. Progression-free
survival time was calculated from the date of the initial surgery
to the onset of clinical deterioration or radiologically confirmed
tumor recurrence.
Telomerase assay
As described previously, the telomerase assay was performed
by a method of the telomeric repeat amplification protocol
(TRAP) (8). The tumor tissues, which had been preserved
at -80℃, were thawed, washed three times with phosphate-
buffered saline (PBS; pH 7.4), dissected into 2-3  L fractions
with sterile scissors, and inserted into the 1.5 mL tubes. Tumor
tissues were homogenized in 200  L ice-cold CHAPS lysis
buffer [10 mM Tris/HCl pH 7.5, 1 mM MgCl2, 1 mM EDTA,
0.1 mM PMSF, 5 mM  -mercaptoethanol, 0.5% CHAPS,
10% glycerol], supplemented with 150 units RNasin (Pro-
mega, Madison, WI, U.S.A.), and incubated for 30 min on
ice. The lysates were centrifuged at 12,000 g for 20 min at
4℃. The supernatants were rapidly frozen and stored at -80
℃. The protein concentration of the supernatant was deter-
mined with the BCA protein assay kit (Pierce, Rockford, IL,
U.S.A.). Supernatant samples equivalent to 200 ng/ L of
protein were assayed in 50  L of reaction mixture comprised
of 20 mM Tris/HCl pH 8.3, 1.5 mM MgCl2, 63 mM KCl,
0.05% Tween 20, 1 mM EGTA, 50  M deoxynucleoside
triphosphates, 0.1  g TS primer (5′ -AATCCGTCGAGCAG-
AGTT-3′ ), 0.1  g TRAP primer mix, and 2 units Taq DNA
polymerase (Gibco-BRL, Gaithersburg, MD, U.S.A.). After
the reaction mixture was incubated for 30 min at room tem-
perature for telomerase-mediated extension of the TS primer,
it was then subjected to 36 polymerase chain reaction (PCR)
cycles at 94℃ for 30 sec, at 53℃ for 30 sec, and at 72℃
for 30 sec. The PCR products were then electrophoresed on
12.5% polyacrylamide gels at 400 V for 25 min and silver
staining (Silver stain kit, Bioneer, Cheongwon, Korea) was
performed. 25 bp DNA stepladders (Promega, Southamp-
ton, U.K.) were used as markers. For every reaction, telom-
erase-positive extracts and PCR/ELISA-positive controls were
used. For each specimen, heat inactivation controls were made
at 85℃for 10 min.
Statistical analysis
For statistical analysis, we used a commercially available
program, SPSS version 9.0 (SPSS Inc., Chicago, IL, U.S.A.)
for Windows. The Kruscal-Wallis test was used to correlate
the expression of telomerase according to the pathological
types of the tumor. The difference among the positive rates
of telomerase activity in the different grades of glial cell tumors
was analyzed by the Mann-Whitney test. Survival of the pati-
ents was plotted by the Kaplan-Meier method, and their differ-
ence was compared by the Log-rank test. A probability value
of less than 0.05 was considered statistically significant. 
RESULTS
Patient characteristics
We included 24 (39%) men and 38 (61%) women in the
study. Their mean age was 41.9±18.5 yr (range, 2-71 yr).
At the time of last follow-up, 11 patients were dead and 22
patients were progressed clinically or radiologically. The medi-
an follow-up period was 26 months (range, 3-44 months).
Fig. 1. TRAP assay for telomerase activity in surgical specimens
of brain tumors. TS oligonucleotides were amplified by PCR, with
the downstream primer CX [5′ -(CCCTTA)3 CCCTAA-3′ ] and the
upstream primer TS, in the presence of internal TRAP assay stan-
dard. Reaction products were resolved on a 12.5% polyacrylamide
gel. The positive control is shown in lane 1 and the molecular weight
marker in lane 2. Telomerase activity is detected as a typical lad-
dering pattern in glioblastomas (lane 3 and 4) and meningioma
(lane 5).
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Telomerase activity and pathological types
Telomerase activity was detected in 39 (63%) out of 62
brain tumors (Fig. 1). Of the 16 cases of astrocytic tumors,
10 cases (63%) showed expression of telomerase activity. Five
(83%) of 6 glioblastomas, 3 (75%) of 4 anaplastic astrocy-
tomas, and 2 (33%) of 6 astrocytomas were positive in telom-
erase activity. Two pineoblastomas showed telomerase activ-
ity; eight (67%) of 12 pituitary adenomas, four (67%) of six
acoustic neurinomas, and 10 (63%) of 16 meningiomas showed
telomerase activity, suggesting a relatively high expression
rate. Nine metastatic brain tumors were found to express
telomerase activity in five (56%) cases. Overall, the expres-
sion rate of telomerase activity showed no significant differ-
ence among pathological types (p>0.05; Table 1). However,
telomerase activity of the glioma showed a definite associa-
tion with the pathological grade (Fig. 2).
Correlation between telomerase activity and survival time
The median survival time of patients with and without
telomerase activity was 21 and 34 months, respectively. The
difference was statistically significant (Fig. 3). There was also
a difference in the median progression-free survival time of
patients with and without telomerase activity (Fig. 4). In
group I, the median survival of patients with and without
telomerase activity was 9 and 18 months, respectively. There
was a significant difference between telomerase-positive and
negative groups (Table 2).
Among group I tumors, the difference in median progres-
sion-free survival time was significant, according to the pres-
ence or absence of telomerase activity. On the other hand,
telomerase activity did not affect the overall survival duration
for patients with group II tumors. In the median progression-
free survival of group II, there was a significant difference
between telomerase-positive and negative tumors (Table 2).
Our data suggest that telomerase activity has a significant
prognostic impact on both overall survival and progression-
free survival for all tumors in the aggressive group. Telom-
erase activity does not affect overall survival in non-aggres-
sive tumors, although it is associated with this group’s pro-
gression-free survival.
Pathological types 
No. of positive 
expressions (%) 
No. of 
deaths
Astrocytic tumors (n=16) 10 (63) 7
Astrocytoma (n=6) 2 (33) 2 
Anaplastic astrocytoma (n=4) 3 (75) 2 
Glioblastoma (n=6) 5 (83) 3 
Pituitary adenoma (n=12) 8 (67) 0
Meningioma (n=16) 10 (63) 1
Acoustic neurinoma (n=6) 4 (67) 0 
Pineoblastoma (n=2) 2 (100) 0 
Hemangioblastoma (n=1) 0 (0) 0 
Metastatic tumor (n=9) 5 (56) 3 
Table 1. Pathological types, expression of telomerase activity,
and status of 62 patients with brain tumors
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Fig. 3. Kaplan-Meier curves demonstrating correlation of telom-
erase activity to the overall survival time in patients with brain tumors
(p=0.0362).
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Fig. 4. Kaplan-Meier curves showing the correlation of telomerase
activity to the progression-free survival time in patients with brain
tumors (p=0.0202).
Telomerase (-) group (n=23)
Telomerase (+) group (n=39)
Telomerase (-) group (n=23)
Telomerase (+) group (n=39)
Fig. 2. Comparison of telomerase activity between high-grade and
low-grade gliomas (p=0.022). Gliomas were divided into two groups,
high-grade gliomas including anaplastic astrocytoma and glioblas-
toma, and low-grade glioma including astrocytoma.
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DISCUSSION
Telomerase consists of RNA which acts as a template for
the simple base pair sequence tracts. A catalytic subunit acts
as a reverse transcriptase on the RNA template. The catalytic
subunit of telomerase was first identified in humans by Har-
rington et al. (14). Telomerase exists in its inactive state in
normal somatic cells, except for adult stem cells and early
embryonic cells. The complete mechanism of its activation
is currently not understood. However, its activity has been
found to increase in neoplastic cells, especially in tumors on
the stomach, lung, brain, breast, hematopoietic system, and
thyroid gland (10, 15-19). Telomerase activity was detected
in 74.1% cytologic specimens and in 85.2% tissue specimens
of breast cancers (16). Moreover, Poremba et al. (20) found
that in neuroblastomas, telomerase activity is a powerful,
independent prognostic marker. It is capable of differentiat-
ing between good and poor outcomes in putative ‘favorable’
clinical or biological subgroups. In neuroepithelial tumors,
telomerase activity was detected in 66 (61.7%) of 107 cases.
It was expressed in 20% for grade II astrocytoma, 40% for
anaplastic astrocytoma, and 72.3% for glioblastomas, respec-
tively (10). In addition, Kudoh et al. (21) found telomerase
activity in 98% of glioblastomas, 86% of anaplastic astrocy-
tomas, 54% of low-grade astrocytomas, 83% of anaplastic
meningiomas, 47% of atypical meningiomas, and 7% of
benign meningiomas. Telomerase activity in brain tumors
including glioma, meningioma, and pituitary adenoma has
been related to their prognosis (9, 11). Moreover, from the
fact that telomerase activity increases in tumors with high
metastatic potential (22), it is suggested that it could be used
as an index in the prediction of metastasis. In our study, telom-
erase activity was higher in high grade gliomas than in low-
grade tumors. This suggested that telomerase can not only
act as a biological marker for malignant potential of the glial
tumors but can also act as a significant prognostic factor. This
is supported by evidence that tumors with absent or low
telomerase activity hold a better prognosis. However, as we
found in the present study, the differences in the activity of
telomerase, according to the degree of histological malignan-
cy, was not statistically significant. This shows that telom-
erase activity cannot be the sole factor in predicting the prog-
nosis of patients with brain tumors. Therefore, preexisting
prognostic factors such as age, performance status of the pati-
ent, and tumor recurrence should still be taken into account. 
Telomerase-positive cells with elongated telomeres increased
survival ability and resistance to apoptosis over cells with
shorter telomeres. Telomerase activity and maintenance of
telomere stability are associated with high resistance to apop-
tosis (12). It is known that the response to the treatment of
epithelial cell tumors found in the head and neck decreases
when the activity of telomerase is high. Also, the survival
period of lung cancer patients was decreased as the activity
of telomerase was increased (18, 23, 24). In the present study,
the telomerase-positive tumor group attained significantly
shorter overall survival and progression-free survival durations
compared to the telomerase-negative tumor group. On the
other hand, the overall survival duration in the non-aggres-
sive tumor group, containing pituitary adenoma, meningioma,
hemangiblastoma, and acoustic neurinoma, was not influ-
enced by telomerase activity. However, the progression-free
survival was significantly different between the telomerase-
positive and negative groups. This may also suggest that
telomerase activity is an important prognostic factor in the
progression of brain tumors.
Since this study shows such dysmorphic results in dealing
with all types of brain tumors, the prognostic significance
of telomerase activity will be made clear if we provide more
confident results using a pathologically homogenous type of
brain tumor.
In conclusion, telomerase activity can be an important prog-
nostic factor in predicting the progression and survival of
patients with brain tumors. However, the median overall
survival is not affected by telomerase activity in non-aggres-
sive tumors. Telomerase may also play a role in the malignant
progression of gliomas.
Brain tumors
Overall survival (months)
Median 95% CI*  p-value
No. of
patients
Progression-free survival (months) 
Median 95% CI*  p-value
All 62 0.0362 0.0202
Telomerase (+) 39 21 14.99±27.01 11 4.15±17.85
Telomerase (-) 23 34 28.99±39.41 18 11.93±24.07
Group I 25 0.0053 0.0071
Telomerase (+) 15 9 5.15±12.85 7 5.73±8.27
Telomerase (-) 10 18 11.53±25.61 14 9.38±18.62
Group II 37 0.2207 0.0058
Telomerase (+) 24 25 24.81±26.19 21 12.23±29.77
Telomerase (-) 13 37 20.65±48.01 34 22.60±51.40
Table 2. Overall and progression-free survival time of the patients with brain tumors
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